CL2015003037A1 - Derivados de triazina - Google Patents

Derivados de triazina

Info

Publication number
CL2015003037A1
CL2015003037A1 CL2015003037A CL2015003037A CL2015003037A1 CL 2015003037 A1 CL2015003037 A1 CL 2015003037A1 CL 2015003037 A CL2015003037 A CL 2015003037A CL 2015003037 A CL2015003037 A CL 2015003037A CL 2015003037 A1 CL2015003037 A1 CL 2015003037A1
Authority
CL
Chile
Prior art keywords
triazine derivatives
disorder
composisions
triazina
imidazo
Prior art date
Application number
CL2015003037A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Allen Chappie
Christopher John Helal
Bethany Lyn Kormos
Jamison Bryce Tuttle
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2015003037A1 publication Critical patent/CL2015003037A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2015003037A 2013-05-02 2015-10-13 Derivados de triazina CL2015003037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
CL2015003037A1 true CL2015003037A1 (es) 2016-04-22

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003037A CL2015003037A1 (es) 2013-05-02 2015-10-13 Derivados de triazina

Country Status (33)

Country Link
US (3) US8933224B2 (enExample)
EP (1) EP2991989B1 (enExample)
JP (1) JP6263606B2 (enExample)
KR (1) KR101770905B1 (enExample)
CN (1) CN105164134B (enExample)
AP (1) AP2015008843A0 (enExample)
AR (1) AR096161A1 (enExample)
AU (1) AU2014261070A1 (enExample)
BR (1) BR112015027760A8 (enExample)
CA (1) CA2910759C (enExample)
CL (1) CL2015003037A1 (enExample)
CR (1) CR20150591A (enExample)
CU (1) CU20150144A7 (enExample)
DK (1) DK2991989T3 (enExample)
DO (1) DOP2015000271A (enExample)
EA (1) EA027936B1 (enExample)
EC (1) ECSP15050110A (enExample)
ES (1) ES2637816T3 (enExample)
GE (1) GEP201706675B (enExample)
MA (1) MA38559B1 (enExample)
MD (1) MD20150103A2 (enExample)
MX (1) MX2015015163A (enExample)
NI (1) NI201500157A (enExample)
NZ (1) NZ712949A (enExample)
PE (1) PE20151940A1 (enExample)
PH (1) PH12015502462A1 (enExample)
SG (1) SG11201508201VA (enExample)
TN (1) TN2015000490A1 (enExample)
TW (1) TWI508966B (enExample)
UA (1) UA111696C2 (enExample)
UY (1) UY35547A (enExample)
WO (1) WO2014177977A1 (enExample)
ZA (1) ZA201508968B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ712949A (en) * 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
MX2022004741A (es) * 2019-10-21 2022-05-16 Sk Biopharmaceuticals Co Ltd Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva.
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Pde10a阻害剤を用いる糖尿病および関連障害の処置方法
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
WO2008041571A1 (en) 2006-09-26 2008-04-10 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
EP2493889B1 (en) * 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
BR112012029994A2 (pt) 2010-05-28 2019-09-24 Biocryst Pharm Inc composto heterocíclicos como inibidores de janus quinase
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
NZ712949A (en) * 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors

Also Published As

Publication number Publication date
EP2991989A1 (en) 2016-03-09
EP2991989B1 (en) 2017-06-28
US20140329820A1 (en) 2014-11-06
AR096161A1 (es) 2015-12-09
ECSP15050110A (es) 2017-08-31
DOP2015000271A (es) 2016-02-29
ES2637816T3 (es) 2017-10-17
EA201591819A1 (ru) 2016-05-31
WO2014177977A1 (en) 2014-11-06
CN105164134B (zh) 2017-09-22
MX2015015163A (es) 2016-02-22
BR112015027760A8 (pt) 2018-05-08
PH12015502462A1 (en) 2016-02-22
PE20151940A1 (es) 2016-01-21
US9145427B2 (en) 2015-09-29
CN105164134A (zh) 2015-12-16
UA111696C2 (uk) 2016-05-25
US9296761B2 (en) 2016-03-29
TN2015000490A1 (fr) 2017-04-06
AU2014261070A1 (en) 2015-10-29
CR20150591A (es) 2016-01-04
CA2910759C (en) 2018-01-16
UY35547A (es) 2014-11-28
TWI508966B (zh) 2015-11-21
KR101770905B1 (ko) 2017-08-23
US20150080401A1 (en) 2015-03-19
JP6263606B2 (ja) 2018-01-17
ZA201508968B (en) 2017-11-29
JP2016517877A (ja) 2016-06-20
CA2910759A1 (en) 2014-11-06
AP2015008843A0 (en) 2015-11-30
US20150353579A1 (en) 2015-12-10
CU20150144A7 (es) 2016-04-25
NZ712949A (en) 2017-04-28
US8933224B2 (en) 2015-01-13
DK2991989T3 (en) 2017-07-31
TW201506027A (zh) 2015-02-16
HK1213885A1 (zh) 2016-07-15
MD20150103A2 (ro) 2016-02-29
SG11201508201VA (en) 2015-11-27
KR20160003234A (ko) 2016-01-08
GEP201706675B (en) 2017-05-25
MA38559B1 (fr) 2018-04-30
EA027936B1 (ru) 2017-09-29
NI201500157A (es) 2015-11-30

Similar Documents

Publication Publication Date Title
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2015003491A1 (es) Compuestos químicos.
CL2016000045A1 (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer.
CR20110103A (es) Heteroarilos sustituidos
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
PE20151793A1 (es) Compuestos heterociclicos moduladores de la piruvato quinasa y composiciones que los contienen
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
CL2017000792A1 (es) Derivados del ácido borónico
MX2015016495A (es) Compuestos de 3,4-dihidroisoquinolin-2 (1h)-ilo.
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
CL2015003037A1 (es) Derivados de triazina